Mr. Wenjie Zhang, aged 54，Chairman of the Board, Executive Director and the Chief Executive Officer of Shanghai Henlius Biotech, Inc.
Mr. Zhang has 25 years of commercial experience in the pharmaceutical industry. Before joining Henlius in March 2019, he was the Executive Director, Marketing for Amgen Japan and Asia Pacific region at first and then being promoted as General Manager of Amgen China where he was leading company’s overall efforts in expanding business into Chinese market and help Chinese patients to access Amgen’s innovative medicines. During his tenure as General Manager, Amgen China has effectively built up its commercial infrastructure, organization, and competency. He successfully launched Repatha® (evolocumab), Amgen’s first product in China. Prior to Amgen, Mr. Zhang worked as Vice President, Oncology for Roche in Shanghai, China, where he was managing a strong team of 850 sales and marketing staff in the oncology franchise marketing business unit. He significantly grew the Roche oncology portfolio including Avastin® (bevacizumab), Tarceva ®(erlotinib) and MABTHERA® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing. Before then, Mr. Zhang served as the head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for Asia Pacific region. He succeeded in launching multiple products in China including Nexavar, Kogenate and Betaferon. Mr. Zhang obtained his MBA from the Yale University School of Management in 1998. He graduated with a B.S. in microbiology from Shandong University in Jinan, China in 1990.